POTENCY AND SELECTIVITY OF THE NON-STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTS
Authors:
- 1 May 1990
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 32 (5) , 623-634
Abstract
A selective inhibitor of aromatase is widely sought for the treatment of postmenopausal women with breast cancer. CGS 16949A has been shown to be a highly selective, potent inhibitor of aromatase in vitro. Its potency as an oestrogen suppressant and its selectivity were examined by treating 24 postmenopausal patients with advanced breast cancer for 4 weeks with doses of 0.3, 1‐0 and 2‐0 mg twice daily. The study was conducted in two parts which compared the two lower doses and the two higher doses separately in a cross‐over design protocol. All doses significantly suppressed serum oestradiol and oestrone levels below pretreatment levels. Cross‐over analysis indicated that the 2.0 mg twice daily dose achieved significantly greater suppression of oestradiol levels than 1‐0 mg twice daily but there was no significant difference between any of the doses in the suppression of oestrone. No significant effects were noted on serum levels of LH, FSH, SHBG, prolactin, testosterone, androstenedione, 17‐ hydroxyprogesterone or cortisol. For the four steroids this was true both for basal samples and those collected after Synacthen stimulation. However, serum aldosterone levels were significantly suppressed by 1‐0 mg twice daily CGS 16949A and further suppressed by 2‐0 mg twice daily. It is concluded that CGS 16949A is a potent oestrogen suppressant in postmenopausal patients but that its effect is not totally selective.Keywords
This publication has 29 references indexed in Scilit:
- Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancerCancer Chemotherapy and Pharmacology, 1987
- A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patientsBritish Journal of Cancer, 1985
- 4-HYDROXYANDROSTENEDIONE IN TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCERThe Lancet, 1984
- Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancerBritish Journal of Cancer, 1983
- Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancerBritish Journal of Cancer, 1983
- Aminoglutethimide dose and hormone suppression in advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1983
- A Standardised Multicentre Procedure for Plasma Gonadotrophin RadioimmunoassayAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1982
- Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivoSteroids, 1981
- The two‐period cross‐over clinical trial.British Journal of Clinical Pharmacology, 1979
- Evidence suggesting 11 β-hydroxylase inhibition during aminoglutethimide administrationMetabolism, 1971